| Ytd | 103.66% | |
| 1y | -32.15% |
| Open | 14.44 | Prev Close | 14.49 | Low | 14.44 | High | 14.44 | Mkt Cap | 18.95M |
| Vol | 6.45K | Avg Vol | 48.60K | EPS | -11.66 | P/E | -1.24 | Forward P/E | -1.51 |
| Beta | -0.23 | Short Ratio | 2.64 | Inst. Own | 50.31% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-07 | 50-d Avg | 11.41 | 200-d Avg | 11.95 | 1yr Est | 7.65 |
PMN310 demonstrated dose-dependent reduction of amyloid-beta oligomers in human cerebrospinal fluid
Roth Capital analyst Boobalan Pachaiyappan initiates coverage on ProMIS Neurosciences (NASDAQ:PMN
Gainers Creative Medical Tech (NASDAQ:CELZ) stock moved upwards by 242.5% to $2.77 during Tuesday&#
Cantor Fitzgerald analyst Pete Stavropoulos initiates coverage on ProMIS Neurosciences (NASDAQ:PM
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates ProMIS Neurosciences (NASDAQ:PMN) w
Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for tra
Shares of TransCode Therapeutics, Inc. (NASDAQ: RNAZ) fell sharply during Friday’s session. TransCo